Preexisting MEK1 Exon 3 Mutations in (V600E/K)BRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors

BRAF inhibitors (BRAFi) induce antitumor responses in nearly 60% of patients with advanced (V600E/K)BRAF melanomas. Somatic activating MEK1 mutations are thought to be rare in melanomas, but their potential concurrence with (V600E/K)BRAF may be selected for by BRAFi. We sequenced MEK1/2 exon 3 in me...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Shi, Hubing, Moriceau, Gatien, Kong, Xiangju, Koya, Richard C., Nazarian, Ramin, Pupo, Gulietta M., Bacchiocchi, Antonella, Dahlman, Kimberly B., Chmielowski, Bartosz, Sosman, Jeffrey A., Halaban, Ruth, Kefford, Richard F., Long, Georgina V., Ribas, Antoni, Lo, Roger S.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2012
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3594852/
https://ncbi.nlm.nih.gov/pubmed/22588879
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-12-0022
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky